Abstract The ability to establish genetic risk models is critical for early identification and optimal treatment of breast cancer. For such a model to gain clinical utility, more variants must be identified beyond those discovered in previous genome-wide association studies (GWAS). This is especially true for women at high risk because of family history, but without BRCA1/2 mutations. This study incorporates three datasets in a GWAS analysis of women with Ashkenazi Jewish (AJ) homogeneous ancestry. Two independent discovery cohorts comprised 239 and 238 AJ women with invasive breast cancer or preinvasive ductal carcinoma in situ and strong family histories of breast cancer, but lacking the three BRCA1/2 founder mutations, along with 294 and 230 AJ controls, respectively. An independent, third cohort of 203 AJ cases with familial breast cancer history and 263 healthy controls of AJ women was used for validation. A total of 19 SNPs were identified as associated with familial breast cancer risk in AJ women. Among these SNPs, 13 were identified from a panel of 109 discovery SNPs, including an FGFR2 haplotype. In addition, six previously identified breast cancer GWAS SNPs were confirmed in this population. Seven of the 19 markers were significant in a multivariate predictive model of familial breast cancer in AJ women, three novel SNPs [rs17663555(5q13.2), rs566164(6q21), and rs11075884(16q22.2)], the FGFR2 haplotype, and three
Introduction
Breast cancer continues to be the most common genderspecific malignancy and a leading cause of death in the United States, accounting for nearly one-third of all new cancers in females (Jemal et al. 2010; Siegel et al. 2011) . Breast cancer ranks as the most common cause of cancer deaths among women between the ages of 20 and 59 years, highlighting the need for accurate risk assessment for women in this age group.
Family history is an important risk factor for breast cancer. The risk of developing breast cancer for a woman with a first-degree affected relative is increased twofold ). The risk is even greater for women with multiple cases in family members. Breast cancer risk may be attributable to mutations in high-penetrance genes such as BRCA1, BRCA2, p53 and PTEN, as well as moderate or low penetrance genes (e.g., CHEK2, ATM, HRAS1, BRIP1, and PALB2), but these mutations account for a relatively small proportion of the heritable risk in these breast cancer families (Easton 1999; Walsh et al. 2006 Walsh et al. , 2010 .
To date genome-wide association studies (GWAS) have used high-density genotyping successfully primarily in European-American populations to identify SNPs associated with breast cancer risk in several genes including FGFR2, TNRC9, MAP3K1, LSP1, CASP8, SLC4A7, NEK10 and COX11 and the 8q and 2q35 chromosomal regions (Ahmed et al. 2009; Easton et al. 2007; Rahman et al. 2007; Stacey et al. 2007 ). However, each of these SNPs is a low penetrance allele that is not adequate to predict individual risk even in combination. Thus, identification of additional risk variants is necessary for prediction of individual risk. In addition, whereas these SNPs are well-represented in European-American groups, their allele frequencies and the attendant risks vary in other populations. This is a general phenomenon. Variability of risk allele frequency and effect size has been observed among major ethnic groups (European, African and Asian) for a panel of complex disease SNPs that had reached genome-wide significance (p B 5 9 10 -8 ) in at least one of the groups (Ntzani et al. 2011) . Other studies point to the importance of controlling for ancestry/ethnicity in designing genetic association studies (Haiman and Stram 2010) .
The current study utilizes the Ashkenazi Jewish (AJ) population, the largest genetic isolate in the United States, comprising 2 % of the total population (Stacey et al. 2007 ). The study of this group reduces the major confounding effect of population stratification and holds the promise of identifying founder mutations and less common mutations not easily identifiable in the general population. Accordingly, GWAS have successfully utilized this homogeneous group to identify disease-associated alleles including a recent study by a member of our group that identified five new risk alleles for Crohn disease, known to have up to fourfold higher prevalence in the AJ population (Kenny et al. 2012) . Similarly, another group identified a new region at chromosome 6q22.33 that is associated with breast cancer in AJ women, and this dataset was used as the starting point for the current study (Gold et al. 2008) .
The current study pays special attention to AJ women that are classified as high-risk for breast cancer based on family history but do not carry any of the three founder BRCA1/2 mutations, and therefore, have no strategy for surveillance/ prevention (Rubinstein 2004) . Whereas there are many advantages to using genetically isolated populations, recruiting large cohorts of these distinct groups can be challenging, and this is further compounded by the need for high-risk women with no known BRCA1/2 mutations. Another potential difficulty is that other known/published risk variants besides BRCA1/2 mutations may not be replicable in these AJ women either. To accommodate for the drop in statistical power that results from the use of smaller cohorts, this study employed a three-step design in which each independent dataset included AJ women with familial breast cancer and an average risk control population to identify genetic variants associated with risk of breast cancer in these AJ women. We identified seven new risk SNPs, one 6-SNP FGFR2 haplotype and confirm six known breast cancer SNPs in the AJ population. These SNPs were then evaluated in a multivariate predictive model and showed moderate discriminatory accuracy for separating familial breast cancer cases from controls among AJ women.
Methods

Patient datasets
The Discovery Phase included 1,008 AJ females from two datasets. The first study group comprised a publicly available dataset provided by Memorial-Sloan Kettering Cancer Center (MSKCC) (Gold et al. 2008 ). In the second dataset, cases were women with invasive breast cancer or preinvasive ductal carcinoma in situ (DCIS) recruited as part of the Breast Cancer Family Registry (BCFR) and unaffected controls without family histories through the New York Cancer Project (NYCP) (John et al. 2004; Mitchell et al. 2004 ). The BCFR cases were recruited at Columbia University in New York, NY (111 patients), Ontario Cancer Center in Toronto, ON (101 patients), the Cancer Prevention Institute of California in Fremont, CA (16 patients), and the Fox Chase Cancer Center in Philadelphia, PA (10 patients). Both the MSKCC and BCFR datasets comprised AJ women with breast cancer from high-risk families (at least three affected relatives in a single lineage for MSKCC and at least one first-or seconddegree affected relative for the BCFR) who do not carry any of the three AJ BRCA1/2 founder mutations (BRCA1-5382insC, BRCA1-185delAG, and BRCA2-6174delT). Average age of diagnosis was 51.0 ± 9.4 for MSKCC and 47.5 ± 10.0 for BCFR. Both study groups included unaffected AJ controls (age-matched to the cases in the BCFR dataset: 47.9 ± 9.8) with no family history of breast cancer. All subjects recruited for this study were considered AJ if they reported that all four grandparents were of Eastern European Jewish ancestry. 239 cases were compared to 294 controls from MSKCC in step one of the Discovery Phase followed by 238 cases and 230 controls from BCFR in step two (Fig. 1) .
For the Replication Phase, 203 cases and 263 controls were recruited at New York University Medical Center (NYUMC). Cases were selected based on having three or more affected relatives in a single lineage (including the proband) and negative for the three BRCA1/2 founder mutations. Average age of diagnosis was 52.2 ± 9.5. Controls were determined to lack personal and family histories of breast cancer and were at least 60-year old at the time of enrollment (68.5 ± 7.0). DNA was extracted from NYUMC samples using the Puregene method (Qiagen).
Genotyping MSKCC samples were genotyped on early-access Affymetrix 500K (EAv3) SNP arrays as described previously (Gold et al. 2008) . BCFR samples were genotyped on commercially available Affymetrix 500K SNP arrays according to manufacturer instructions. There is an overlap Fig. 1 -8 ) with breast cancer in other populations thereby having the greatest chance of replicating in the AJ population Fletcher et al. 2011; Hunter et al. 2007; Li et al. 2011; Long et al. 2010; Stacey et al. 2007 ; Thomas et al. 2009; Turnbull et al. 2010; Zheng et al. 2009 ). One of these assays failed, leaving 33 known breast cancer SNPs for analysis.
Data analysis
All genetic analyses were performed using PLINK (Purcell et al. 2007 ). 533 MSKCC and 468 BCFR samples were used in the final analysis for the Discovery Phase. IBD/IBS analysis (PLINK genome command) was used to eliminate subjects who were identical or closely related to others within or between the two datasets (IBD C 0.46, IBS C 0.85; IBD/IBS [ 0.99 for identical subjects). Principle components analysis (PCA; R software) was used to confirm AJ ancestry and remove six outlier subjects showing different or more admixed ancestry in the combined MSKCC and BCFR datasets versus reference HapMap3 populations. The utility of PCA for determining AJ ancestry has been previously demonstrated (Need et al. 2009 ). In the current study, the subjects who were removed were C5 standard deviations from the mean for at least one of the first ten principle components (data not shown). All patient samples had at least 90 % genotype calls so none were removed based on this.
SNPs that had genotyping rates \95 % or minor allele frequencies \1 % were excluded. For the remaining SNPs, Chi-square association analyses were performed on minor allele counts (0, 1, 2) and genotype distributions between cases and controls. In addition to standard association analyses, the CLUMP command was used to identify regions of SNPs in moderate linkage disequilibrium (LD). SNPs within a region spanning 1,000 kb and an LD threshold of r 2 = 0.5 were considered, if an index SNP had p \ 0.01 and CLUMP SNPs had p \ 0.05.
Subjects and SNPs for the Replication Phase were subject to the same QC filtering as that performed for the Discovery Phase. Chi-square association analyses for both minor allele count (0, 1, or 2) and genotype distribution were performed. Haplotype analysis was also performed using the blocks function in PLINK. Pooled p values and odds ratios (ORs) were obtained by combining the three datasets for Chi-square association analysis. We also calculated and reported the Fisher meta p value from p values of three independent cohorts. Common measures of heterogeneity for meta analysis including Cochran's Q statistic and I 2 statistic (Higgins et al. 2003) were calculated and reported for each of the SNPs in Tables 1, 2, 3. The NYUMC replication dataset was also used to evaluate utility in the multivariate models in terms of the discriminatory accuracy of the identified 19 SNP panel. Number of risk alleles for each SNP was used as an independent predictor in binary logistic regression analysis of the GLM function using SPSS v.19 with phenotype (cases versus controls) as the dependent variable. For each individual patient, each SNP was assigned a score (0, 1, or 2) based on the number of risk alleles. For FGFR2 a gene score was based on the total number of risk alleles across all six FGFR2 SNPs (0-12) for each person was used. Two redundant TOX3 SNPs were removed, only leaving the SNP (rs3112612) in the multivariate model. Five other SNPs were removed based on p [ 0.05 (rs16882214, rs12906542, rs16956185, rs5965136, and rs889312) in the multivariate logistic model. A receiver operating characteristic (ROC) curve was constructed using the final panel of seven markers, and area under the ROC curve (AUC) was calculated to measure the power of the panel to distinguish breast cancer occurrence from controls. The predictive model was cross-validated using the ROC R package in the R platform. The NYUMC cohort was randomly split 50:50 to generate two new sub-cohorts. Onethousand iterations were performed, and at each iteration the model was fit using the first sub-cohort and tested using the second sub-cohort. A ROC curve was generated and AUC values calculated for the second cohort at each iteration. An average cross-validation AUC with empirical 95 % confidence interval values is reported.
Results
Seven new candidate SNPs are identified in association with familial breast cancer in AJ women
To identify familial breast cancer risk variants, we designed a GWAS workflow that utilized two separate datasets for the Discovery Phase and a third dataset for the Replication Phase (Fig. 1 ). Quality control (QC) filtering (see ''Methods'') resulted in 332,483 SNPs for Step 1 and 384,565 SNPs for Step 2 of the Discovery Phase. Overlapping top-ranked SNPs from both steps revealed 84 SNPs that were potentially associated with breast cancer in both the MSKCC and BCFR datasets (with Fisher combined p B 0.001). An additional two SNPs that were highly significant (p \ 10 -7 ) in the BCFR dataset but untested in the MSKCC dataset were also carried forward.
In addition, trying to take advantage of the relative genetic homogeneity of the AJ population, we identified shared ancestral haploblocks to find risk variants. A method for long-range haplotyping to investigate changes in linkage disequilibium (LD) patterns between breast cancer patients and controls (utilizing the CLUMP function in PLINK) was used to identify less significant SNPs that might otherwise be masked by the more significant risk variants . We have identified 15 SNPs in seven regions that overlap between the MSKCC and BCFR datasets using this method (data not shown).
In
Step 3 (the Replication Phase), the 101 SNPs from standard association analysis in addition to long-range haplotyping were tested in a third AJ dataset of high-risk familial breast cancer cases versus hyper-controls (AJ women with no family history and at least 60-year old). Allelic (Amitage trend test) and genotypic Chi-square tests revealed seven new candidate SNPs with pooled p values across the phases, totaling 680 cases and 787 controls, ranging from 9.15 9 10 -3 to 6.67 9 10 -6 (allelic v 2 ) and 3.82 9 10 -4 to 7.12 9 10 -6 (genotypic v 2 ) (Table 1) . SNPs previously reported to have significant associations in the MSKCC GWAS were re-examined in the BCFR and NYUMC datasets (Table 2a) . Since a slightly different subset of the MSKCC subjects was used (removing subjects closely related to each other or to subjects in the BCFR dataset), the p values reported here vary somewhat from those published. The FGFR2 SNP, rs1078806, was determined to be significant in the NYUMC Replication cohort (Table 2a) as well as the BCFR Discovery dataset and similar effects, indicated by the odds ratios, were observed among all three datasets. rs7203563 (A2BP1) was significant in the BCFR dataset (p = 2.43 9 10 -2 ) and rs3012642 (PHKA1/HDAC8) nearly reached significance in this dataset (p = 5.37 9 10 -2 ), but neither SNP was significant in the NYUMC dataset. Similar odds ratios were also observed for the four ECHDC1/RNF146 SNPs in the BCFR and NYUMC datasets as that previously reported for the MSKCC dataset.
We chose five additional SNPs for haplotype analysis of FGFR2, based on Discovery Phase results plus published data. Analysis of a 6-SNP FGFR2 haplotype (rs11200014, rs2981579, rs1078806, rs1219648, rs2420946, rs2981582) revealed a significant minor (risk) allele haplotype (AAGGTA) in the cases (47.9 %) compared to controls (36.7 %, p = 2.18 9 10 -4 ) in the NYUMC Replication cohort (Table 2b ). This result agrees with the findings of a previous study of AJ women that identified a haplotype of four FGFR2 SNPs [rs11200014 (A), rs2981579 (A), rs1219648 (G), and rs2420946 (T)] significantly associated with breast cancer (p = 5.90 9 10 -3 ; OR = 1.25) (Raskin et al. 2008) . Our findings are similar, adding two additional SNPs [rs1078806 (G) and rs2981582 (A)] for a MA minor allele, MAF minor allele frequency for cases (''A'') and controls (''U''), p values based on v 2 test on allele counts between cases and controls Hum Genet (2013) 132:523-536 529 longer haplotype in association with breast cancer in AJ women. In total, 113 SNPs from Discovery cohorts were carried forward to the Replication Phase, the top 84 from standard association analysis, 2 highly significant SNPs in the BCFR cohort that were absent from the platform used for MSKCC, 15 from LD Clumping, 7 from the original MSKCC analysis, and 5 additional SNPs for haplotype analysis. Custom SNP assays for 4 of the top 84 SNPs failed, leaving 109 SNPs tested in the NYUMC Replication cohort. Significant associations (p \ 0.05) were indicated in 13 of these 109 SNPs (11.9 %) in the Replication Phase.
Six previously identified SNPs were potentially associated with AJ familial breast cancer risk In addition to the 113 SNPs identified in the Discovery Phase, we tested 34 SNPs previously reported to be associated with breast cancer risk, either in the AJ population or having reached genome-wide significance in other populations (p B 5 9 10 -8 ), many of which were not present on the Affymetrix 500K array used in MSKCC and BCFR. One of the custom SNP assays failed. Six of the remaining 33 assays for known breast cancer SNPs (18.2 %) were significant in the NYUMC dataset (Table 3 , p \ 0.05). Three of these six known SNPs were on the 500K arrays and the data for the MSKCC and BCFR datasets are presented here as well.
SNPs moderately predict familial breast cancer risk in AJ women
We investigated the 19 SNPs [7 new candidate SNPs, the 6-SNP FGFR2 haplotype and the 6 previously published BC SNPs that were confirmed (p \ 0.05) in our population], for their ability to discriminate between AJ familial breast cancer cases and AJ controls. Scores for individual SNPs (0, 1, or 2 risk alleles) plus a gene score for FGFR2 (0-12 risk alleles) were used in stepwise logistic regression analysis comparing cases versus controls from the NYUMC replication dataset. SNPs with p [ 0.05 were eliminated one-by-one, resulting in a final list of six SNPs plus the FGFR2 gene score that significantly contributed to this risk model (Fig. 2) . This list included three new SNPs [rs17663555(5q13.2), rs566164(6q21), and rs11075884 (16q22.2)] and three known SNPs [rs13387042 (2q35), rs2046210 (ESR1), and rs3112612 (TOX3)]. The table in Fig. 2 shows the effect of each genotype (0, 1 or 2 risk alleles) or FGFR2 gene score as a covariate in the model. The predictive accuracy of the model was reflected in an AUC of 0.74 (95 %CI 0.69, 0.79) for the ROC curve. Cross-validation analysis generated an average AUC of 0.67 (95 %CI 0.62, 0.72).
Discussion
The notion of 'common disease-common variant' has come under scrutiny in part because of the inability to identify enough variants to explain most of the heritability of complex diseases, such as breast cancer (Cazier and Tomlinson 2010; McClellan and King 2010) . GWAS have identified several reproducible SNPs, but these high-frequency (MAF [ 5 %), low-penetrance (\1.5-fold increase in risk) alleles account only for a small percentage of familial breast cancer risk (Harlid et al. 2012) . At the same time, studies have revealed a strong impact of population structure on common-versus-rare allelic variation and the need for more focus on ancestry in GWAS (Gravel et al. 2011; Guthery et al. 2007 ). In one study of the four major US populations (African, Asian, European, and Hispanic), more than half of the common SNPs (MAF C 10 %) were shared among the four populations, but only one-third of these SNPs were common in all four populations (Guthery et al. 2007 ). More than half of all of the tested SNPs were private, occurring only in one of the four populations. Also, synonymous variants were more commonly shared among the populations than non-synonymous or nonsense mutations, indicating the presence of more recent, deleterious mutations in distinct populations.
Several GWAS have likewise identified disease-associated variants in the AJ population that were not previously identified in other populations. In addition to Crohn disease, AJ population studies have aided in the discovery of variants associated with Parkinson disease, bipolar disorder, and schizophrenia (Fallin et al. 2004; Liu et al. 2011; Shifman et al. 2006) . Similar to the Crohn study, one group confirmed common variants associated with Parkinson disease in people of European origin, but also identified six new variants. While some of these disease-variants have and will replicate in non-AJ populations, it is clear that using subjects with homogeneous ancestry will, at the very least, facilitate the discovery of SNPs that are present at lower frequencies in members of that heterogeneous group.
The majority of the breast cancer SNPs identified to date, particularly those that have reached genome-wide significance, have been discovered using study populations of European ancestry. Likewise, commercial genotyping platforms have been designed with particular attention to more common variants, so odds are in favor of identifying only common risk alleles or common alleles that tag the actual causal variant. The AJ population is a genetically isolated one that harbors rare and private variants that are present at a much higher frequency in this group than the general population, such as the BRCA1/2 founder mutations. European ancestry is a major contributor to AJ genetics, and our data indicated six known breast cancer SNPs that seemingly survived admixture in this population (and more than these 6 are likely to be significant if our sample sizes are larger). But studying this population has allowed us to identify seven additional variants that have not yet been linked to breast cancer, and it is expected that using denser coverage and larger sample sizes will reveal still more risk alleles.
Among the known breast cancer SNPs tested in the Replication Phase, seven were originally identified in the MSKCC dataset (Gold et al. 2008) . Statistical significance was not reached for four of these SNPs in the BCFR dataset and for six of the SNPs in the NYUMC dataset, though similar odds ratios were consistently observed across all three cohorts. Thus, it is likely that all of these SNPs would have achieved significance had the sample sizes been larger. Minor differences in study design may also have contributed to the observed differences in allele frequencies among cases and controls. Similar strategies were used for recruiting the cases at MSKCC, BCFR and NYUMC, selecting women with C3 affected in a single lineage at MSKCC and NYUMC and women with an average 2.86 cases of breast cancer per family through BCFR, but control recruitment differed for the NYUMC dataset as compared to the Discovery Phase groups. Women aged 60 years or older were selected to exclude the chance of an early breast cancer diagnosis. The MSKCC controls were not selected based on age, but controls used in the BCFR dataset were age-matched to the cases. Similarly, phase 2 of the original MSKCC study (Gold et al. 2008 ) did select age-matched controls but did not select cases based on family history, and phase 3 utilized sporadic breast cancer cases. Two SNPs (rs7203563 and rs3012642) were not significant in phase 3 of the original MSKCC study, but it is unclear if this is a result of the use of sporadic cases. The remaining five SNPs were validated in both of the MSKCC phase 2 and 3 datasets. In the current study it is most likely that sample size impacted the results observed in the BCFR and NYUMC datasets because the observed odds ratios are all similar to the MSKCC group. Indeed, in the three phases of the original MSKCC study p value ranges vary with the size of the respective datasets: phase 1 (548 subjects, p values = 8.9 9 10 -4 to 4.5 9 10 -2 ), phase 2 (1,929 subjects, p values = 9.8 9 10 -5 to 3.3 9 10 -3 ), and phase 3 (430 subjects, p values = 1.8 9 10 -2 to 0.57). Pooled p values were examined for the three datasets in our study, for a total of 1,467 subjects and the range was 1.70 9 10 -6 to 4.10 9 10 -2 . Fisher meta p value from p values of the three independent cohorts was calculated and reported together with common measures of heterogeneity for meta analysis including Cochran's Q statistic and I 2 statistic. Also, complete clinical data may reveal phenotypic subtype(s) with which some SNPs are more strongly associated.
To our knowledge, breast cancer risk models that do not incorporate BRCA1 or BRCA2 mutations have not been previously attempted for the AJ population. Cases in our study groups are without BRCA1/2 mutations. To assess usefulness of the identified markers in predicting AJ familial breast cancer cases versus AJ controls, we constructed a preliminary model using the NYUMC group starting with14 markers: seven new candidate SNPs, a gene score for FGFR2 and six previously identified SNPs. We arrived at a 7-marker panel in a stepwise manner, eliminating 7 of the 14 SNPs that were not significant in the multivariate model (p [ 0.05). More details on the construction of the multivariate logistic model can be found in the ''Data analysis'' section. In short, the model based on the seven markers achieved an AUC of 0.74 (95 % CI 0.69, 0.79). However, it is important to note that since the NYUMC cohort was used to evaluate discovery SNPs and to construct the risk model, the model is subject to some degree of over-fitting or overestimation of the predictability. For this reason, cross-validation of the model was performed revealing an AUC of 0.67 (95 %CI 0.62, 0.72) .
It is clear that many more SNPs of similar effect size will be required to predict familial breast cancer risk more accurately in AJ women. However, we provide evidence here of progress towards that goal, achieving moderate discriminatory accuracy with a panel of just seven markers. It might also be valuable to test the Breast Cancer Risk Assessment Tool BCRAT data, based on age at menarche, age at first live birth, number of first-degree relatives with breast cancer, and number of previous benign breast biopsies, combined with this SNP panel. These clinical covariates have previously been shown with modest predictability for breast cancer risk (Gail et al. 2008; Wacholder et al. 2010) . Unfortunately, these covariates were not measured in this current study. Unlike the previous study, though, the NYUMC dataset was recruited to include controls without family histories of breast cancer. It will be necessary to recruit high-risk controls and cases to test the current model and build a potentially better predictive model.
Finally, six of the seven candidate SNPs newly identified in this study that reside in chromosomal regions previously linked to cancer. Deletions in 6q21 and 16q22.2 and gains in Xq12 have each been associated with breast cancer (Kuukasjarvi et al. 1997; Negrini et al. 1994; Nordgard et al. 2008) . Likewise, amplification of 6p22.3 has been linked to multiple cancers including bladder and hereditary prostate cancer (Janer et al. 2003; Veltman et al. 2003) . 18p11.22 has been linked to lung cancer and 5q13.2 deletions to chemoresistant ovarian tumors, colorectal cancer, and chondrosarcomas (Ahn et al. 2012; Dyrso et al. 2011; Hameed et al. 2009; Kim et al. 2007 ). However, we were unable to directly determine the specific biological relevance for these SNPs. GWAS SNP arrays were designed to detect common alleles with the assumption that they themselves are causal alleles or that they tag those that are. It is possible that the low-penetrance risk SNPs identified here are actually tagging causal high-penetrance mutations undetectable at this point due to low frequency and/or incomplete coverage of variants. Complete analysis using whole genome or exome sequencing might make the hunt for the alleles with the largest effect on their respective diseases feasible.
One of the new SNPs [rs5965136(Xq12)], however, was rare in this population and exhibited a large effect (pooled OR for the risk allele = 4.78). Therefore, another possible explanation is that the genes in proximity to these SNPs are not fully annotated, or that the SNPs affect genes further away. As more eQTL data become available, the function of these SNPs may be revealed.
We have addressed the need for better utilizing ancestry in GWAS to identify new candidate SNPs for predicting breast cancer risk in a specific population. One limitation to this study is the relatively small sample size resulting in limited power to achieve genome-wide significance or replicate known variants. This limitation might be the main cause for the insignificance of the 27 previously identified breast cancer SNPs in the NYUMC cohort, many of which had reached genome-wide significance in other studies. As mentioned earlier, some of the SNPs found to be associated with breast cancer risk in different populations may not be replicable in the AJ population without BRCA1/2 mutations even with a larger sample size. Nonetheless, our goal for examining these previously published SNPs in the NYUMC cohort was to identify potential candidates that might be useful in the context of building multivariate risk prediction models. Another limitation was the incomplete coverage of variants on the SNP arrays available at the onset of the study, impeding the detection of rare and/or causal variants. Similarly, there was incomplete coverage of SNPs in the MSKCC dataset compared to the BCFR dataset due to the use of early-access versus commercially available Affymetrix 500K arrays. As a result, about 13 % of the SNPs genotyped in the BCFR cohort were not genotyped in the MSKCC cohort. Since 111 SNPs were identified from the 435,632 genotyped SNPs (0.025 %), we expect that successful imputation of the remaining SNPs in the MSKCC cohort would have resulted in an approximately additional 17 SNPs for further testing in the NYUMC cohort, 1-2 of which may have been of interest. As high-density genotyping data from next-generation sequencing for the AJ population become available, imputation for missing and untyped SNPs, as well as genotyping of rare and/or casual variants, will become more achievable. Finally, because we were already limited by sample size we did not divide the cohorts further by stage or histopathological subtype. Rather this study was designed to identify common predispositional risk factors for AJ women across subtypes of breast cancer.
The major strength of this study lies in the use of three independent, genetically homogeneous populations for identification of new potential risk alleles, and strong, consistent effects were observed for several SNPs across all three independent datasets. Seven new candidate SNPs were identified, three of which contributed to a preliminary risk model. While moderate predictive power was accomplished, complete coverage of genetic variants (e.g., nextgeneration sequencing) combined with clinical and demographic data in a larger cohort will undoubtedly result in a more powerful model for predicting individual risk for this and other homogeneous populations.
